ImmunoPrecise Antibodies Ltd. (IPA.V)
| Previous Close | 8.51 |
| Open | 8.50 |
| Bid | 8.27 x 0 |
| Ask | 8.33 x 0 |
| Day's Range | 8.25 - 8.50 |
| 52 Week Range | 6.39 - 26.25 |
| Volume | 21,224 |
| Avg. Volume | 103,085 |
| Market Cap | 157.402M |
| Beta (5Y Monthly) | -0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.21 |
| Earnings Date | Mar. 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
VICTORIA, British Columbia, September 09, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for first quarter fiscal year 2022, which ended July 31, 2021.
- Business Wire
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
VICTORIA, British Columbia, September 08, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company’s subsidiary, IPA Europe, has been granted a three-year approval for the "Crédit d'Impôt Recherche" (CIR) from the French Ministry of Higher Education and Research. CIR is a French R&D tax credit initiative
- Business Wire
ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
VICTORIA, British Columbia, September 07, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021.
